Cocrystal Pharma, Inc. 8-K

What Happened
On May 26, 2026, Cocrystal Pharma, Inc. (COCP) filed a Form 8-K under Item 7.01 (Regulation FD Disclosure) to disclose a press release about the company’s novel direct-acting antivirals. The press release was furnished as Exhibit 99.1 to the 8-K.

Key Details

• Filing date: May 26, 2026 (Form 8-K filed with the SEC).
• Item reported: 7.01 — Regulation FD Disclosure (public announcement).
• Exhibit: Press release furnished as Exhibit 99.1.
• No earnings, financial results, officer changes, or transaction disclosures were reported in this filing.

Why It Matters
This 8-K is a public disclosure that Cocrystal issued news about its antiviral programs; investors should read the attached press release for the full details on any clinical, regulatory, or business updates. The filing itself does not include financial results or other material corporate actions, so any market impact will depend on the substance of the press release.